Key result
Elevated admission free fatty acids linked to ~2.8-fold higher 3-month mortality in acute heart failure.
Why the study?
Plasma free fatty acids are elevated in heart failure and may reflect disease severity, leading to the hypothesis that serum FFA levels predict 3-month mortality in acute heart failure.
Are admission serum free fatty acid levels associated with 3-month mortality in acute heart failure patients?
Cohort (n=152)
No
Are admission serum free fatty acid levels associated with 3-month mortality in acute heart failure patients?
Odds Ratio: 2.76 (95% CI 1.32–6.27)
p-value: p=0.010
Elevated admission serum free fatty acid levels serve as a prognostic marker independently associated with 3-month mortality in acute heart failure.
May aid risk stratification in acute HF; hypothesis-generating for FFA as independent prognostic marker.
Background Plasma free fatty acids (FFA) are higher in heart failure (HF) patients compared to healthy controls. Considering that the extent of FFA elevation in HF might mirror the severity of HF, we hypothesized that the serum levels of FFA may be a useful prognostic indicator for 3-month mortality in acute heart failure (AHF). Methods We analyzed the serum samples of AHF patients obtained at admission to the emergency department. Serum levels of FFA were analyzed using an enzymatic reagent on an automatic analyzer. Results Out of 152 included AHF patients that were originally included, serum samples of 132 patients were available for the quantification of FFA. Of these, 35 (26.5%) died within 3 months of onset of AHF. These patients had significantly higher serum levels of FFA compared to AHF patients who were alive 3 months after onset of AHF. Univariable logistic regression analyses showed a significant positive association of FFA levels with 3-month mortality (odds ratio [OR] 2.76 [95% confidence interval 1.32-6.27], p = 0.010). Importantly, this association remained significant after adjusting for age and sex, as well as for further clinical and laboratory parameters that showed a significant association with 3-month mortality in the univariate analyses. Conclusions We conclude that the admission serum levels of FFA are associated with 3-month mortality in AHF patients. Therefore, measurements of circulating FFA levels may help identifying high-risk AHF patients.
No takes yet. Share an insight, caveat, or question.
Degoricija et al. (2019) conducted a cohort in Acute Heart Failure (AHF) (n=152). Elevated admission serum free fatty acids (FFA) was evaluated on 3-month mortality (OR 2.76, 95% CI 1.32-6.27, p=0.010). Elevated admission serum free fatty acid levels were significantly associated with increased 3-month mortality in patients with acute heart failure (OR 2.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: